CRISPR Therapeutics AG and Vertex Pharmaceuticals have completed and submitted the rolling Biologics License Applications (BLAs) to the FDA for the investigational treatment exagamglogene autotemcel (exa-cel) for sickle cell disease and transfusion-dependent beta thalassemia.